Parabilis Medicines
Parabilis Medicines Raises $305M Series F | Precision Medicine Platform
Parabilis Medicines Closes $305M Series F
Parabilis Medicines, a biotechnology company developing precision medicines, has raised $305 million in Series F funding.
The round was co-led by RA Capital Management, Fidelity, and Janus Henderson Investors.
Key Highlights
- Late-stage biotech funding
- Focus on precision medicine
- Strong institutional backing
Company Overview
Parabilis Medicines is advancing a pipeline of precision medicines targeting genetic drivers of disease, with multiple programs in clinical development.
Company Info
Investors (3)
Share
Related Reports
Basecamp Research Raises $140M Series C for AI-Designed Medicines
Basecamp Research raised a $140 million Series C led by S32 to train new EDEN models and advance AI-designed therapeutics toward clinical development.
Ema Raises $77M Series B to Expand Its Enterprise AI Employee Platform
Ema raised a $77 million Series B led by Creaegis, bringing total funding to $140 million as it scales AI agents across enterprise workflows.
Chamelio Raises $26M Series A for AI-Native Legal Operations
Chamelio raised a $26 million Series A led by Entrée Capital to replace legacy contract-management systems with agentic legal operations.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free